Merck & Co (MRK) AI Analysis

MRK$147.19-0.86 -0.58%
Drug Manufacturers - GeneralMega CapHigh Quality
Compare
Market cap$362.86BEnterprise value$415.14BRevenue (TTM)$67.30BMarket positionTop 5%

Score

39
Bearish
Value
31
Quality
61
Growth
26

AI Score 55. Merck & Co., Inc. has a high price-to-earnings ratio of approximately 153.4, indicating overvaluation relative to earnings

Summary

Merck & Co., Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The shares offer a dividend yield of 2.3%.

Valuation

The stock trades at a P/E ratio of 151.4 and a price-to-book ratio of 8.8. These multiples indicate a demanding valuation based on the provided measures.

Quality

Net margin is 3.6%, indicating profitability, though the provided information does not include balance-sheet, cash-flow, or return metrics.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data are provided, so growth cannot be assessed from the available facts.

Risks

The elevated P/E ratio of 151.4 creates valuation risk if earnings do not support the multiple. The net margin of 3.6% also provides limited evidence of profitability strength without additional operating context.

Merck & Co (MRK) AI Analysis

MRK price $147.19 -0.86 -0.58%

Ticker
MRK
Price
$147.19
Change
-0.86 -0.58%
Market cap
$362.86B
P/E
148.79
Forward P/E
17.59
Dividend yield
2.26%
Beta
0.22
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
39
Value
31
Quality
61
Growth
26

Stocklytics score rationale: value 31, quality 61, growth 26.

AI Score 55. Merck & Co., Inc. has a high price-to-earnings ratio of approximately 153.4, indicating overvaluation relative to earnings

Summary

Merck & Co., Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The shares offer a dividend yield of 2.3%.

Valuation

The stock trades at a P/E ratio of 151.4 and a price-to-book ratio of 8.8. These multiples indicate a demanding valuation based on the provided measures.

Quality

Net margin is 3.6%, indicating profitability, though the provided information does not include balance-sheet, cash-flow, or return metrics.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data are provided, so growth cannot be assessed from the available facts.

Risks

The elevated P/E ratio of 151.4 creates valuation risk if earnings do not support the multiple. The net margin of 3.6% also provides limited evidence of profitability strength without additional operating context.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener